BRAIN has concluded an agreement with Wilde Cosmetics on the sale of all shares in the loss-making Monteil Cosmetics International held by BRAIN to Wilde Cosmetics. The transaction will be completed on 30 June 2019. The contracting parties have agreed not to disclose financial details.
Monteil Cosmetics International GmbH, based in Düsseldorf, is represented as a brand company in the cosmetics end customer business (B2C). It has been part of the BRAIN Group since 2011. Most recently, BRAIN held 68.3% of the Monteil shares, while Wilde Cosmetics acted as a minority shareholder. The sale of the loss-making investment will unburden the BRAIN Group both financially and in terms of capacity and allow it to concentrate fully on the further expansion of the product-scalable B2B business.
“The focus of the BRAIN Group is on growing the product business with industrial partners. The companies in our group are now fully specialized in R&D and B2B business. This is where we see the absolute strengths of the group, which we are continuously expanding”, says Dr. Jürgen Eck, CEO of BRAIN.
“We have taken a further step towards consistently implementing our strategy. The pure B2B cosmetics business is and will remain part of the growth strategy”, says Ludger Roedder, CBO of BRAIN.
About BRAIN
B.R.A.I.N. Biotechnology Research and Information Network a European technology company in the field of industrial biotechnology, the core discipline of Bioeconomy. As such, BRAIN identifies previously untapped, efficient enzymes, microbial producer organisms or natural substances from complex biological systems that can be put to industrial use. The innovative solutions and products developed by help of this “Toolbox of Nature” are successfully applied in the chemistry, the cosmetics and the food industries. BRAIN’s business model is based on two pillars. The BioScience segment comprises mainly of the research and development business with industrial partners (the “Tailor-Made Solutions” cooperation business), and the company’s own research and development. The BioIndustrial segment consists mainly of the industrially scalable products business.
For more information, please click here.